3HRES/3HRE联合脱氧核苷酸钠治疗初治继发性肺结核临床疗效及安全性

摘要

目的 评价脱氧核苷酸钠治疗初治继发性肺结核临床疗效及安全性.方法 94例初治继发性肺结核患者随机分为对照组47 例与试验组47 例,对照组给予标准化疗方案,3HRES/3HRE;试验组在对照组的基础上给予脱氧核苷酸钠注射液150 mL +5％葡萄糖注射液体250 mL 静脉滴注,1 次/d.均以28 d 为1 个周期,连续治疗1 周期.比较2 组临床疗效、治疗前后血清糖链抗原125(CA125)、糖链抗原199(CA199)、肝肾功能以及不良反应发生情况.结果 治疗后,对照组临床总有效率为78.72％,显著低于试验组的93.62％( P <0.05).2 组治疗后血清CA125、CA199水平均显著降低,且试验组显著小于对照组( P <0.05);血清ALT、AST、Cr及BUN浓度水平与治疗前相比,差异无统计学意义.对照组不良反应发生率为6.38％,试验组为10.64％,差异无统计学意义.结论 脱氧核苷酸钠治疗初治继发性肺结核的临床疗效显著,安全性高.%Objective To evaluate the efficacy and safety of deoxyribonucleotide natrium in the treatment of secondary pulmonary tuberculosis.Methods A total of 94 cases with secondary pulmonary tuberculosis included in this study were dividing into control group and experiment group with each 47 cases.The patients in the both groups were give regular treatment.Patients in the control group were given standard chemotherapy regimen 3HRES/3HRE and patients in the experiment group revieved sodium deoxyribonucleotide injection 150mL+5％injection of liquid glucose 250mL by intravenous drip with once a day.1 time/d,two groups of patients with a cycle of 28d,a total of one cycles of treatment.The clinical efficacy,CA125,CA199,function of liver and kidney,occurrence of adverse reactions were compared between the two groups.Results The clinical efficacy in experiment group was 94.44％,which significant higher than that in control group 75.00％(P<0.05).The serum level of CA125 and CA199 decreased after treatment with experiment group much lower than the control group(P<0.05).Compared with the control group,the ALT,AST,Cr and serum BUN levels before and after treatment,the difference was not statistically significant.The adverse drug reactions was not statistically different between the two groups.Conclusion Deoxyribonucleotide natrium in the treatment of secondary pulmonary tuberculosis was effective with high safety.